
    
      UHE-103 cream is an investigational combination drug to treat moccasin type tinea pedis, a
      fungal infection that affects the feet and toes. Eligible subjects will be assigned to one of
      the 5 possible treatment groups and participate for a total of 6 weeks. Subjects will apply
      their assigned test drug twice daily for 2 weeks. Each subject will then be assessed for
      safety and efficacy at week 4 and week 6. There will be a total of 5 clinic visits: 1
      screening/baseline visit (Day 1), 2 treatment visits (Days 8 and 15), and 2 follow-up visits
      (Days 29 and 43).
    
  